AlphaWire

newswire

Abb Vie Cuts Full-Year Earnings Guidance After Apogee Deal as Second-Quarter Profit Surges

2026-07-31·newswire-us-stock-175814
Abb Vie Cuts Full-Year Earnings Guidance After Apogee Deal as Second-Quarter Profit Surges.

AbbVie lowered its full-year adjusted earnings guidance after factoring in the impact of its planned $10.9 billion acquisition of Apogee Therapeutics, even as the drugmaker reported higher second-quarter profit and revenue. The company said Friday that the acquisition is expected to reduce 2026 earnings per share by $0.14.

Stronger-than-expected earnings so far this year are expected to partly offset the negative impact. AbbVie finalized the approximately $10.9 billion Apogee acquisition last month to strengthen its core immunology pipeline. The transaction is expected to close in the third quarter.

It will add Apogee's investigational drug zumilokibart, which is being developed to treat moderate-to-severe atopic dermatitis, the most common type of eczema. The drug could compete with Dupixent, which is jointly developed by Regeneron Pharmaceuticals and AbbVie.

AbbVie now expects full-year adjusted earnings per share of $13.87 to $14.07, compared with its previous forecast of $13.91 to $14.11. The FactSet consensus estimate is $14.06. AbbVie shares fell 2.20% in early trading.

The company reported second-quarter net income of $3.61 billion, or $2.03 per share, compared with net income of $938 million, or $0.52 per share, in the year-earlier period. Excluding one-time items, adjusted earnings per share were $3.65, above analysts' estimate of $3.60.

Revenue rose 10% from a year earlier to $16.99 billion, exceeding Wall Street's estimate of $16.78 billion. Immunology revenue increased 15% to $8.79 billion, driven by Skyrizi and Rinvoq, which are used to treat arthritis and Crohn's disease, respectively. Neuroscience revenue jumped 20% to $3.23 billion.

Growth in those businesses offset pressure from declining oncology revenue and essentially flat revenue in the aesthetics business.

#Stocks #Earnings

Full text

Abb Vie Cuts Full-Year Earnings Guidance After Apogee Deal as Second-Quarter Profit Surges

AbbVie lowered its full-year adjusted earnings guidance after factoring in the impact of its planned $10.9 billion acquisition of Apogee Therapeutics, even as the drugmaker reported higher second-quarter profit and revenue. The company said Friday that the acquisition is expected to reduce 2026 earnings per share by $0.14. Stronger-than-expected earnings so far this year are expected to partly offset the negative impact. AbbVie finalized the approximately $10.9 billion Apogee acquisition last month to strengthen its core immunology pipeline. The transaction is expected to close in the third quarter. It will add Apogee's investigational drug zumilokibart, which is being developed to treat moderate-to-severe atopic dermatitis, the most common type of eczema. The drug could compete with Dupixent, which is jointly developed by Regeneron Pharmaceuticals and AbbVie. AbbVie now expects full-year adjusted earnings per share of $13.87 to $14.07, compared with its previous forecast of $13.91 to $14.11. The FactSet consensus estimate is $14.06. AbbVie shares fell 2.20% in early trading. The company reported second-quarter net income of $3.61 billion, or $2.03 per share, compared with net income of $938 million, or $0.52 per share, in the year-earlier period. Excluding one-time items, adjusted earnings per share were $3.65, above analysts' estimate of $3.60. Revenue rose 10% from a year earlier to $16.99 billion, exceeding Wall Street's estimate of $16.78 billion. Immunology revenue increased 15% to $8.79 billion, driven by Skyrizi and Rinvoq, which are used to treat arthritis and Crohn's disease, respectively. Neuroscience revenue jumped 20% to $3.23 billion. Growth in those businesses offset pressure from declining oncology revenue and essentially flat revenue in the aesthetics business.

AbbVie lowered its full-year adjusted earnings guidance after factoring in the impact of its planned $10.9 billion acquisition of Apogee Therapeutics, even as the drugmaker reported higher second-quarter profit and revenue.

The company said Friday that the acquisition is expected to reduce 2026 earnings per share by $0.14. Stronger-than-expected earnings so far this year are expected to partly offset the negative impact.

AbbVie finalized the approximately $10.9 billion Apogee acquisition last month to strengthen its core immunology pipeline. The transaction is expected to close in the third quarter. It will add Apogee's investigational drug zumilokibart, which is being developed to treat moderate-to-severe atopic dermatitis, the most common type of eczema. The drug could compete with Dupixent, which is jointly developed by Regeneron Pharmaceuticals and AbbVie.

AbbVie now expects full-year adjusted earnings per share of $13.87 to $14.07, compared with its previous forecast of $13.91 to $14.11. The FactSet consensus estimate is $14.06.

AbbVie shares fell 2.20% in early trading.

The company reported second-quarter net income of $3.61 billion, or $2.03 per share, compared with net income of $938 million, or $0.52 per share, in the year-earlier period.

Excluding one-time items, adjusted earnings per share were $3.65, above analysts' estimate of $3.60.

Revenue rose 10% from a year earlier to $16.99 billion, exceeding Wall Street's estimate of $16.78 billion.

Immunology revenue increased 15% to $8.79 billion, driven by Skyrizi and Rinvoq, which are used to treat arthritis and Crohn's disease, respectively. Neuroscience revenue jumped 20% to $3.23 billion.

Growth in those businesses offset pressure from declining oncology revenue and essentially flat revenue in the aesthetics business.

← Back to archive